<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-2-18-11-2025-shutterstock_2309849697-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-2-18-11-2025-shutterstock_2309849697-430x241.jpg"/></p>
<p>Halozyme 拥有专有酶 rHuPH20，支撑 Enhanze，这是一种快速皮下药物递送的解决方案。图片来源：SaiArLawKa2/Shutterstock.com。</p>
<p>Merus 和 Halozyme 签署了一项全球非独占合作和许可协议，用于 petosemtamab 的皮下制剂。</p>
<p>该协议涉及使用 Enhanze 药物递送技术开发和商业化 petosemtamab 的给药，该药物是一种表皮生长因子受体 (EGFR) 与富含亮氨酸重复的 G 蛋白偶联受体 5 (LGR5) 的双特异性抗体。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - Lemzoparlimab 在边缘区 B 细胞淋巴瘤中的应用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - Lemzoparlimab 在腹膜癌中的应用</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>Merus 授权 Halozyme 的 Enhanze 技术，以加速皮下给药的进展。</p>
<p>Halozyme 将获得预付款、与商业里程碑和销售成功相关的额外付款，以及在特许权使用费期间对使用该技术制备的 petosemtamab 的净销售额的低至中单数字的特许权使用费。</p>
<p>Merus 首席运营官兼总法律顾问 Peter Silverman 表示：“Petosemtamab 在众多实体肿瘤癌症的临床研究中继续显示出令人鼓舞的结果，并有潜力成为头颈癌及其他领域的首个和最佳治疗方案。</p>
<p>“我们很自豪能与 Halozyme 合作，并期待与他们的团队密切合作进行皮下给药。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预测？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>了解更多关于战略情报</p>
<p>Halozyme 总裁兼首席执行官 Dr Helen Torley 表示：“我们很高兴能与 Merus 合作，推进 r/m HNSCC 患者及其他潜在适应症的治疗选择。</p>
<p>“这次合作代表了我们 Enhanze 技术改善治疗效率和提升患者治疗体验的新机会。我们共同的目标是加速患者和医疗提供者的创新。”</p>
<p>Halozyme 拥有酶 rHuPH20，支撑 Enhanze，这是一种快速皮下药物递送的解决方案，以减轻患者的治疗负担。</p>
<p>Enhanze 技术已被包括 Takeda、Roche、Janssen、Pfizer 和 AbbVie 在内的公司许可。</p>
<p>在 2025 年 9 月，Genmab 签署了一项协议 以每股 97 美元的价格收购 Merus 的所有股份，此次全现金交易的估值为 80 亿美元，增强了其肿瘤学管线。</p>
<h2>制药技术卓越奖 - 参赛的好处</h2>
<p>获得你应得的认可！制药技术卓越奖 庆祝创新、领导力和影响力。通过参赛，你展示了你的成就，提升了你的行业形象，并将自己定位于推动制药进步的顶尖领导者之中。不要错过脱颖而出的机会——今天就提交你的参赛作品！</p>
<p>立即提名</p>

奥洛兹美医疗

MRUS

<p>Merus 和 Halozyme 已达成全球非独占合作和许可协议，涉及皮下给药形式的 petosemtamab。这项合作包括使用 Halozyme 的 Enhanze 技术来增强 petosemtamab 的递送，该药物是一种 EGFR x LGR5 双特异性抗体。Halozyme 将获得预付款、里程碑付款和版税。该合作旨在改善多种癌症的治疗选择，包括头颈癌。两家公司对其对患者和医疗服务提供者的潜在益处表示乐观</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-2-18-11-2025-shutterstock_2309849697-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-2-18-11-2025-shutterstock_2309849697-430x241.jpg"/></p>
<p>Halozyme owns proprietary enzyme rHuPH20, underpinning Enhanze, a solution for rapid subcutaneous drug delivery. Credit: SaiArLawKa2/Shutterstock.com.</p>
<div class="lb-trans"><p>Halozyme 拥有专有酶 rHuPH20，支撑 Enhanze，这是一种快速皮下药物递送的解决方案。图片来源：SaiArLawKa2/Shutterstock.com。</p>
</div><p>Merus and Halozyme have signed a worldwide non-exclusive partnership and licence agreement for subcutaneous formulation of petosemtamab.</p>
<div class="lb-trans"><p>Merus 和 Halozyme 签署了一项全球非独占合作和许可协议，用于 petosemtamab 的皮下制剂。</p>
</div><p>The agreement involves the development and commercialisation of the administration of petosemtamab, an epidermal growth factor receptor (EGFR) times leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) bispecific antibody, using Enhanze drug delivery technology.</p>
<div class="lb-trans"><p>该协议涉及使用 Enhanze 药物递送技术开发和商业化 petosemtamab 的给药，该药物是一种表皮生长因子受体 (EGFR) 与富含亮氨酸重复的 G 蛋白偶联受体 5 (LGR5) 的双特异性抗体。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Lemzoparlimab in Marginal Zone B-cell Lymphoma</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Lemzoparlimab 在边缘区 B 细胞淋巴瘤中的应用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Lemzoparlimab in Peritoneal Cancer</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Lemzoparlimab 在腹膜癌中的应用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Merus licensed Halozyme’s Enhanze technology to accelerate advancement for the subcutaneous administration.</p>
<div class="lb-trans"><p>Merus 授权 Halozyme 的 Enhanze 技术，以加速皮下给药的进展。</p>
</div><p>Halozyme will receive an upfront fee, additional payments linked to commercial milestones and sales success from Meru, and low to mid single-digit royalties on net sales of petosemtamab formulated with the technology during the royalty period.</p>
<div class="lb-trans"><p>Halozyme 将获得预付款、与商业里程碑和销售成功相关的额外付款，以及在特许权使用费期间对使用该技术制备的 petosemtamab 的净销售额的低至中单数字的特许权使用费。</p>
</div><p>Merus chief operating officer and general counsel Peter Silverman stated: “Petosemtamab continues to show encouraging results in the clinical studies across numerous solid tumour cancers and has the potential to become a first and best in class treatment in head and neck cancer and beyond.</p>
<div class="lb-trans"><p>Merus 首席运营官兼总法律顾问 Peter Silverman 表示：“Petosemtamab 在众多实体肿瘤癌症的临床研究中继续显示出令人鼓舞的结果，并有潜力成为头颈癌及其他领域的首个和最佳治疗方案。</p>
</div><p>“We are proud to collaborate with Halozyme and look forward to working closely with their team on a subcutaneous administration.”</p>
<div class="lb-trans"><p>“我们很自豪能与 Halozyme 合作，并期待与他们的团队密切合作进行皮下给药。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预测？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>Halozyme president and CEO Dr Helen Torley stated: “We are excited to collaborate with Merus to advance treatment options for patients with r/m HNSCC and other potential indications.</p>
<div class="lb-trans"><p>Halozyme 总裁兼首席执行官 Dr Helen Torley 表示：“我们很高兴能与 Merus 合作，推进 r/m HNSCC 患者及其他潜在适应症的治疗选择。</p>
</div><p>“This collaboration represents a new opportunity for our Enhanze technology to improve treatment efficiency and enhance the patient treatment experience. Together, we aim to accelerate innovation for patients and healthcare providers.”</p>
<div class="lb-trans"><p>“这次合作代表了我们 Enhanze 技术改善治疗效率和提升患者治疗体验的新机会。我们共同的目标是加速患者和医疗提供者的创新。”</p>
</div><p>Halozyme owns the enzyme rHuPH20 which underpins Enhanze, a solution enabling rapid subcutaneous drug delivery to lessen the treatment burden on patients.</p>
<div class="lb-trans"><p>Halozyme 拥有酶 rHuPH20，支撑 Enhanze，这是一种快速皮下药物递送的解决方案，以减轻患者的治疗负担。</p>
</div><p>The Enhanze technology has been licensed by companies including Takeda, Roche, Janssen, Pfizer and AbbVie.</p>
<div class="lb-trans"><p>Enhanze 技术已被包括 Takeda、Roche、Janssen、Pfizer 和 AbbVie 在内的公司许可。</p>
</div><p>In September 2025, Genmab signed an agreement to buy all shares of Merus at $97 per share, in an all-cash transaction valued at $8bn, boosting its oncology pipeline.</p>
<div class="lb-trans"><p>在 2025 年 9 月，Genmab 签署了一项协议 以每股 97 美元的价格收购 Merus 的所有股份，此次全现金交易的估值为 80 亿美元，增强了其肿瘤学管线。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 参赛的好处</h2>
</div><p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
<div class="lb-trans"><p>获得你应得的认可！制药技术卓越奖 庆祝创新、领导力和影响力。通过参赛，你展示了你的成就，提升了你的行业形象，并将自己定位于推动制药进步的顶尖领导者之中。不要错过脱颖而出的机会——今天就提交你的参赛作品！</p>
</div><p>Nominate Now</p>
<div class="lb-trans"><p>立即提名</p>
</div>

Merus BV 和奥洛兹美医疗在皮下注射 petosemtamab 方面展开合作